Various adverse cutaneous reactions to anti-TNF-α monoclonal antibody have been reported. In clinical studies with infliximab (Remicade®) adverse drug reactions were most frequently reported in the respiratory system and in the skin and appendages. We describe here 6 patients receiving anti- TNF-α therapy (infliximab) for Crohn’s disease or rheumatoid arthritis who consulted our out-patient department for adverse cutaneous reactions between November 1999 and February 2002. The following diagnoses were made: leukocytoclastic vasculitis, lichenoid drug reaction, perniosis-like eruption (2 patients), superficial granuloma annulare and acute folliculitis.

Keywords:
Anti-TNF-α monoclonal antibody, Infliximab, Crohn’s disease, Rheumatoid arthritis
1.
O’Quinn RP, Miller JL: The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: A report of 2 cases. Arch Dermatol 2002;138:644–648.
2.
Newland MR, Weinstein A, Kerdel F: Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 2002;41:449–452.
3.
Dotan I, Yeshurun D, Hallak A, Horowitz N, Tiomny E, Reif S, Halpern Z, Rachmilewitz D: Treatment of Crohn’s disease with anti TNF alpha antibodies – The experience in the Tel Aviv Medical Center. Harefuah 2001;140:289–293, 368.
4.
Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P: Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000;27:841–850.
5.
Chan AT, Cleeve V, Daymond TJ: Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 2002;78:47–48.
6.
European Agency for the Evaluation of Medicinal Products: http://www.emea.eu.int/pdfs/human/press/pus/444500en.pdf.
7.
Moore N, Biour M, Paux G, Loupi E, Bagaud B, Boismare F, Royer RJ: Adverse drug reaction monitoring: Doing it the French way. Lancet 1985;ii:1056–1058.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.